Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2431 to 2445 of 9010 results

  1. Ruxolitinib for treating moderate atopic dermatitis ID6602

    In development Reference number: GID-TA11809 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Vertebral body tethering for idiopathic scoliosis in children and young people

    Awaiting development Reference number: GID-HTG10657 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  3. Semaglutide for managing overweight and obesity in children 6 to 11 years [TSID12381]

    Awaiting development Reference number: GID-TA12020 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Povorcitinib for treating prurigo nodularis [TSID12385]

    Awaiting development Reference number: GID-TA12018 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Pelabresib with ruxolitinib for treating myelofibrosis [TSID12391]

    Awaiting development Reference number: GID-TA12017 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Nipocalimab for treating generalised myasthenia gravis in people 2 to 17 yearslimab for Myasthenia gravis [TSID12382]

    Awaiting development Reference number: GID-TA12015 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Lemborexan for treating insomnia [TSID12397]

    Awaiting development Reference number: GID-TA12011 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Depemokimab for treating eosinophilic granulomatosis with polyangiitis [TSID12383]

    Awaiting development Reference number: GID-TA12007 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Crovalimab for treating atypical haemolytic uraemic syndrome [TSID12386]

    Awaiting development Reference number: GID-TA12006 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Amlitelimab for treating moderate to severe atopic dermatitis in people 12 years and over [TSID12394]

    Awaiting development Reference number: GID-TA12005 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Olomorasib with pembrolizumab for untreated KRAS G12C mutation- and PD-L1-positive unresectable advanced non-small-cell lung cancer [TSID12375]

    Awaiting development Reference number: GID-TA12003 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Olomorasib in combination for untreated KRAS G12C mutation-positive unresectable advanced non-squamous non-small-cell lung cancer [TSID12376]

    Awaiting development Reference number: GID-TA12001 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Procalcitonin to guide decisions on stopping antibiotics in people with confirmed or highly suspected sepsis

    Awaiting development Reference number: GID-HTG10536 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  14. KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication

    Awaiting development Reference number: GID-HTG10530 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  15. Artificial intelligence (AI) technologies to help detect fractures on X-rays in urgent care

    Awaiting development Reference number: GID-HTG10531 Expected publication date: TBC

    HealthTech guidance
    Awaiting development